Patents Examined by Wu-Cheng Winston Shen
  • Patent number: 9446041
    Abstract: The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: November 30, 2015
    Date of Patent: September 20, 2016
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Anna K. Bassil, Soren Beinke, Rabinder Kumar Prinjha
  • Patent number: 9427436
    Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: August 30, 2016
    Assignee: Pharnext
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov
  • Patent number: 9408856
    Abstract: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 9, 2016
    Assignee: TEMPLE UNIVERSITY—OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Arthur G Schwartz, John R Williams
  • Patent number: 9409889
    Abstract: The present invention relates to amino-substituted imidazopyridazine compounds of general formula (I); in which A, R1, R2, R3, R4, R5 and n are as defined in the claims, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.
    Type: Grant
    Filed: March 27, 2013
    Date of Patent: August 9, 2016
    Assignee: BAYER PHARMA AKTIENGESELLSCHAFT
    Inventors: Knut Eis, Florian Puehler, Ludwig Zorn, Volker Schulze, Detlev Sülzle, Philip Lienau, Andrea Hägebarth, Kirstin Petersen, Ulf Bömer
  • Patent number: 9408405
    Abstract: The present invention relates to the use of one or more compounds that are capable of increasing the serum level of insulin-like growth factor 1 (IGF-1) for the preparation of a therapeutical composition, in particular in the form of a food supplement, for the treatment of subjects suffering from serious fatigue and exhausting symptoms, burn-out and chronic fatigue syndrome. The same composition can also be used by patients suffering from depression, Alzheimer disease, irritated bowel syndrome, osteoporosis, type 2 diabetes, or for anti-aging, immune therapy and recovery after exercise. The composition also has a use in veterinary applications for increasing the growth and immunity in animals.
    Type: Grant
    Filed: October 3, 2003
    Date of Patent: August 9, 2016
    Assignee: Veijlen N.V.
    Inventors: Hubert Jean Marie François Gillessen, Christian Rebiere
  • Patent number: 9402853
    Abstract: The present invention relates to formulations of poorly water soluble pharmaceutical agents of Formula I and II. The present invention also relates to compositions containing compounds of Formula I or II, and glucocorticoids, and methods for reducing side effects from glucocorticoid treatment by co-administration of compounds of Formula I and II. The compositions herein are useful for the treatment of diabetes and obesity related diseases including metabolic syndrome.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: August 2, 2016
    Assignee: TEMPLE UNIVERSITY-OF THE COMMONWEALTH OF HIGHER EDUCATION
    Inventors: Arthur G Schwartz, John R Williams
  • Patent number: 9393252
    Abstract: The present invention is directed to antiviral compositions that provide efficacy against non-envelope viruses such as noroviruses. The antiviral compositions comprise an alcohol and a synergistic combination of an aromatic carboxylic acid and an aromatic hydroxyamide. The composition may be used as a topical on human skin, as a hand sanitizer or as a hard surface cleaning composition.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: July 19, 2016
    Assignee: ECOLAB USA INC.
    Inventors: Daniel E. Pedersen, Hilina Emiru, Carter Martin Silvernail
  • Patent number: 9393241
    Abstract: The present invention relates to compositions and methods for the treatment of the Charcot-Marie-Tooth disease and related disorders.
    Type: Grant
    Filed: February 24, 2014
    Date of Patent: July 19, 2016
    Assignee: PHARNEXT
    Inventors: Daniel Cohen, Serguei Nabirochkin, Ilya Chumakov
  • Patent number: 9393308
    Abstract: Disclosed herein are a nanopreparation having a micelle structure for diagnosis or treatment of cancer diseases, and a method of preparing the same, and more particularly, a nanopreparation having a micelle structure available for diagonosis or treatment of cancer diseases and a method for preparing the same, wherein the nanopreparation is prepared by encapsulating a photosensitizer by forming micelle with polymeric lipid DSPE-mPEG. The nanopreparation having the micelle structure according to the present invention has a size of 12 nm or less by encapsulating hypericin, which is a photosensitizer, by forming micelle with polymeric lipid DSPE-mPEG having a molecular weight of 1500 to 2500. Resultingly, the nanopreparation easily overcomes a blood-tumor barrier (BTB) and an interstitial fluid pressure and has light induced cytotoxicity efficiency that is about more than 2.5 times higher than that of the case where hypericin is used alone.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: July 19, 2016
    Assignee: Korea Advanced Institute of Science and Technology
    Inventors: Chulhee Choi, Kyuha Chong, Jiho Park
  • Patent number: 9388195
    Abstract: Provided is a compound useful for the prophylaxis or treatment of cancer. The present invention relates to a compound represented by formula (I): wherein each symbol in the formula is as defined in the specification, or a salt thereof or a prodrug thereof, which is useful for the prophylaxis or treatment of cancer.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: July 12, 2016
    Assignee: Takeda Pharmaceutical Company Limited
    Inventors: Misaki Homma, Toru Miyazaki, Yuya Oguro, Osamu Kurasawa
  • Patent number: 9388127
    Abstract: The invention generally relates to compounds that function as TP antagonists for treating thrombosis and other cardiovascular, renal, or pulmonary diseases. In some embodiments, the invention provides a compound including a substituted nitro phenoxy phenyl, a sulfonylurea, and an alkyl group. In some embodiments, the invention provides a method of treating thrombosis by administering an antithrombotic compound that preferentially binds to a thromboxane receptor, has preferential binding for either TPalpha (TP?) or TPbeta (TP?) receptor subtype.
    Type: Grant
    Filed: April 17, 2013
    Date of Patent: July 12, 2016
    Assignee: UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN
    Inventors: B. Therese Kinsella, Patrick Guiry, Helen Reid, Barry O'Connor
  • Patent number: 9375482
    Abstract: The present invention provides compositions and methods relating to polylactides which may be used for drug delivery (e.g., parenteral delivery), wherein an organic solvent is not required.
    Type: Grant
    Filed: April 22, 2014
    Date of Patent: June 28, 2016
    Assignee: University of Geneva
    Inventors: Michael Moller, Thomas Trimaille, Robert Gurny
  • Patent number: 9365579
    Abstract: The invention provide a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomer and isomer thereof wherein the variable are defined herein. The compound of the invention are useful for treating immunological and oncological conditions.
    Type: Grant
    Filed: January 30, 2015
    Date of Patent: June 14, 2016
    Assignee: AbbVie Inc.
    Inventors: Neil Wishart, Maria A. Argiriadi, David J. Calderwood, Anna M. Ericsson, Bryan A. Fiamengo, Kristine E. Frank, Michael M. Friedman, Dawn M. George, Eric R. Goedken, Nathan S. Josephsohn, Biqin C. Li, Michael J. Morytko, Kent D. Stewart, Jeffrey W. Voss, Grier A. Wallace, Lu Wang, Kevin R. Woller
  • Patent number: 9339057
    Abstract: The present invention relates to a composition comprising a synergetic mixture of flavorings or flavoring substances and organic acids. Moreover, the present invention relates to the use of said composition as a preservative for animal foodstuffs and additives intended preferably for monogastric animals.
    Type: Grant
    Filed: September 4, 2012
    Date of Patent: May 17, 2016
    Assignee: VETAGRO INTERNATIONAL S.R.L.
    Inventors: Andrea Piva, Maurizio Tedeschi
  • Patent number: 9340570
    Abstract: Chemical entities that are novel compounds, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: April 29, 2013
    Date of Patent: May 17, 2016
    Assignee: NeuPharma, Inc.
    Inventor: Xiangping Qian
  • Patent number: 9340546
    Abstract: The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors. The compounds of this invention have formula I: or a pharmaceutically acceptable salt, wherein the variables are as defined herein. Moreover, The compounds of this invention have formula I-A: or a pharmaceutically acceptable salt, wherein the variables are as defined herein.
    Type: Grant
    Filed: December 6, 2013
    Date of Patent: May 17, 2016
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Nadia Ahmad, Dean Boyall, Jean-Damien Charrier, Chris Davis, Rebecca Davis, Steven Durrant, Gorka Etxebarria I Jardi, Damien Fraysse, Juan-Miguel Jimenez, David Kay, Ronald Knegtel, Donald Middleton, Michael O'Donnell, Maninder Panesar, Francoise Pierard, Joanne Pinder, David Shaw, Pierre-Henri Storck, John Studley, Heather Twin
  • Patent number: 9333192
    Abstract: The present invention provides compositions comprising optimized ratios of Red clover phytoestrogens as determined by a proprietary physiologically based pharmacokinetic and pharmacodynamic model. The compositions are useful for modulating bone remodeling, and prevention and treatment of osteoporosis.
    Type: Grant
    Filed: April 2, 2014
    Date of Patent: May 10, 2016
    Assignee: SINOVEDA CANADA, INC
    Inventors: Yun Kau Tam, Yi-Chan James Lin, Brian Duff Sloley, Chih-Yuan Tseng
  • Patent number: 9328081
    Abstract: Chemical entities that are curcumin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.
    Type: Grant
    Filed: August 29, 2012
    Date of Patent: May 3, 2016
    Assignee: NEUPHARMA, INC.
    Inventor: Xiangping Qian
  • Patent number: 9315487
    Abstract: Tetrahydroquinoline compounds pharmaceutical compositions containing such compounds and their use in therapy.
    Type: Grant
    Filed: May 2, 2012
    Date of Patent: April 19, 2016
    Assignee: GlaxoSmithKline LLC
    Inventors: Dominique Amans, Emmanuel Hubert Demont, Katherine Louise Jones, Jonathan Thomas Seal, Ann Louise Walker
  • Patent number: 9303002
    Abstract: Compounds and compositions comprising compounds that inhibit glutaminase are described herein. Also described herein are methods of using the compounds that inhibit glutaminase in the treatment of cancer.
    Type: Grant
    Filed: November 21, 2013
    Date of Patent: April 5, 2016
    Assignee: AGIOS PHARMACEUTICALS, INC.
    Inventors: Rene M. Lemieux, Janeta Popovici-Muller, Francesco G. Salituro, Jeffrey O. Saunders, Jeremy Travins, Shunqi Yan